Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853486 | 1.00 | NPSR1 (0.61) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL22070543 | 0.86 | CYP4F2 (0.58) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL14924014 | 0.86 | TRPV1 (0.47) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL15026335 | 0.86 | NPSR1 (0.49) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL28068831 | 0.85 | MAOB (0.64) | ALDH1A1PKMHDAC4HDAC3HDAC1 | |
| SCHEMBL28068830 | 0.85 | MAOB (0.64) | ALDH1A1PKMHDAC4HDAC3HDAC1 | |
| SCHEMBL69146 | 0.84 | NPSR1 (0.74) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL271386 | 0.84 | NPSR1 (0.74) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL4210529 | 0.84 | KDM4E (0.59) | NPSR1KDM4EALDH1A1PKMHDAC4 | |
| SCHEMBL3557934 | 0.84 | KDM4E (0.59) | NPSR1KDM4EALDH1A1PKMHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-20180086886-A1 | PHOTOCROSSLINKABLE GROUP-CONTAINING COMPOSITION FOR COATING STEPPED SUBSTRATE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-03-29 | — | — | US | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| WO-2009018344-A1 | ANTICANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| CN-1250528-C | Cyclic nitrones and pharmaceutical compositions containing them | AWENTIS PHARMACEUTICAL INC (US) | 2006-04-12 | — | — | CN | disclosed |
| CN-1500779-A | Cyclic nitrones and pharmaceutical compositions containing them | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1500787-A | Cyclic nitrones and pharmaceutical compositions containing them | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1196050-A | Cyclic nitrones and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (US) | 1998-10-14 | — | — | CN | disclosed |
| EP-0142324-B1 | PHENYLALKANOIC ACID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-01-04 | — | — | EP | disclosed |
| US-4668698-A | [(4-phenyl-1,3-dioxan-cis-5-yl)alkyl]phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-26 | — | — | US | disclosed |
| EP-0142324-A2 | Phenylalkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | NPSR1 1150/4885KDM4E 169/4885ALDH1A1 378/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | NPSR1 1150/4885KDM4E 169/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.